Physician profile
Erika Cadle
NPI 1598233959
$4,999.99
in general payments reported to CMS, 2019-2025
33 companies · $1,268 in 2025
The $1,268 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $18.65 · 2023: $1,696 · 2024: $2,017 · 2025: $1,268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,981.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,981.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $808.22 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $696.67 | 2023-2025 | |
| Pfizer INC. | $520.04 | 2023-2025 | |
| Novo Nordisk INC | $460.05 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $284.71 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $277.81 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $239.50 | 2023-2024 | Verquvo, Vaxneuvance, Belsomra |
| Takeda Pharmaceuticals U.S.A., INC. | $212.82 | 2023-2025 | Trintellix |
| Amgen INC. | $202.54 | 2023-2025 | Evenity, Prolia, Otezla |
| Glaxosmithkline, LLC. | $144.19 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $140.42 | 2023-2024 | Spravato |
| Exact Sciences Corporation | $117.99 | 2023-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $112.34 | 2024-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.22 | 2023-2024 | Tradjenta, Jardiance, Synjardy |
| Axsome Therapeutics, INC. | $74.81 | 2023-2025 | Auvelity |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $72.71 | 2024-2025 | Voquezna |
| Mylan Specialty L.P. | $64.90 | 2024 | Yupelri |
| Xeris Pharmaceuticals, INC. | $57.42 | 2024 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $50.53 | 2023-2024 | |
| Antares Pharma, INC. | $49.78 | 2024 | Xyosted |
| Halozyme INC | $43.15 | 2023 | |
| Gilead Sciences, INC. | $42.70 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $36.28 | 2025 | Rexulti |
| Esperion Therapeutics, INC. | $31.18 | 2025 | Nexletol |
| Tolmar, INC. | $29.41 | 2023-2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $25.79 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $24.28 | 2024 | Crysvita |
| Pulmonx Corporation | $22.11 | 2024 | Chartis Catheter, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
| Boston Scientific Corporation | $19.01 | 2025 | Watchman Flx |
| Daiichi Sankyo INC. | $18.48 | 2023 | Injectafer |
| Dynavax Technologies Corporation | $13.96 | 2024 | Heplisav-B |
| Astellas Pharma US INC | $13.57 | 2024 | Veozah |
| Kowa Pharmaceuticals America, INC. | $13.40 | 2023 | Seglentis, Livalo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erika Cadle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.